全文获取类型
收费全文 | 255篇 |
免费 | 11篇 |
国内免费 | 12篇 |
专业分类
儿科学 | 13篇 |
妇产科学 | 2篇 |
基础医学 | 12篇 |
口腔科学 | 2篇 |
临床医学 | 30篇 |
内科学 | 59篇 |
皮肤病学 | 1篇 |
神经病学 | 3篇 |
特种医学 | 54篇 |
外科学 | 62篇 |
综合类 | 3篇 |
预防医学 | 8篇 |
药学 | 9篇 |
肿瘤学 | 20篇 |
出版年
2022年 | 3篇 |
2021年 | 3篇 |
2019年 | 2篇 |
2018年 | 4篇 |
2017年 | 1篇 |
2016年 | 1篇 |
2015年 | 4篇 |
2014年 | 5篇 |
2013年 | 5篇 |
2012年 | 3篇 |
2011年 | 4篇 |
2010年 | 3篇 |
2009年 | 9篇 |
2008年 | 6篇 |
2007年 | 12篇 |
2006年 | 9篇 |
2005年 | 9篇 |
2004年 | 11篇 |
2003年 | 8篇 |
2002年 | 9篇 |
2001年 | 8篇 |
2000年 | 11篇 |
1999年 | 8篇 |
1998年 | 10篇 |
1997年 | 4篇 |
1996年 | 10篇 |
1995年 | 5篇 |
1994年 | 16篇 |
1993年 | 11篇 |
1992年 | 6篇 |
1991年 | 5篇 |
1990年 | 4篇 |
1989年 | 8篇 |
1988年 | 10篇 |
1987年 | 13篇 |
1986年 | 5篇 |
1985年 | 6篇 |
1984年 | 2篇 |
1983年 | 2篇 |
1982年 | 3篇 |
1981年 | 7篇 |
1980年 | 4篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1975年 | 3篇 |
1969年 | 1篇 |
1966年 | 1篇 |
排序方式: 共有278条查询结果,搜索用时 365 毫秒
271.
272.
273.
Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation 总被引:13,自引:0,他引:13
Although the majority of factor VII (FVII) circulates in the zymogen form, low levels of activated factor VII (FVIIa) have been postulated to exist in plasma and to serve a priming function for triggering of the clotting cascade. However, direct measurement of plasma FVIIa has not previously been possible. We have quantified plasma FVIIa levels using a novel, highly sensitive assay that is free from interference by FVII. Specificity of this clot-based assay results from the use of a mutant tissue factor that is selectively deficient in promoting FVII activation, but retains FVIIa cofactor function. In normal adults, FVIIa was found to be present in plasma (mean: 3.6 ng/mL) with considerable variation between individuals (range: 0.5 to 8.4 ng/mL). FVIIa levels were only loosely correlated with FVII coagulant activity, but were elevated in pregnancy and reduced with oral anticoagulant therapy. Incubation of plasma on ice in glass containers (cold activation) resulted in substantial FVIIa generation. Measurement of plasma forms of factor VII is of potential clinical importance because elevated FVII coagulant activity has been implicated as a significant risk predictor for ischemic heart disease. Clinically, this new assay will now permit direct assessment of the role of plasma FVIIa in thrombotic disorders. 相似文献
274.
275.
276.
João C Belloti Marcel JS Tamaoki Alvaro N Atallah Walter M Albertoni João BG dos Santos Flavio Faloppa 《BMC musculoskeletal disorders》2010,11(1):137
Background
At present, there is no conclusive evidence regarding the best treatment method for reducible unstable fractures of the distal radius. This study compared the effectiveness of two methods used in surgical treatment of such fractures: percutaneous pinning and external fixation. 相似文献277.
Purpose
Bivalirudin use for anticoagulating patients undergoing cardiac surgery, particularly those with or at risk for heparin-induced thrombocytopenia, has expanded over the past several years. The purpose of this review is to provide a summary of the following: the differences between indirect and direct thrombin inhibition, unfractionated heparin’s limitations (i.e., heparin-induced thrombocytopenia), bivalirudin’s pharmacology, recent cardiac surgery trials comparing bivalirudin and unfractionated heparin as anticoagulants, the growing role of bivalirudin-mediated anticoagulation for various surgical procedures, and the potential of bivalirudin-mediated vascular graft patency.Source
A systematic search of the English literature was performed using PubMed from the United States National Library of Medicine. Pertinent articles from 1992-2010 were obtained from this search, and their reference lists were used to retrieve additional relevant articles.Principal findings
In small studies in the cardiac surgery arena, bivalirudin has demonstrated a similar safety and efficacy profile compared with unfractionated heparin. Bivalirudin’s role as an anticoagulant in various cardiac surgical procedures (i.e., heart transplant) and vascular surgical procedures is growing and reviewed. Additionally, the molecular basis for the potential for bivalirudin-mediated improvement in vascular graft patency after coronary artery bypass graft procedures is discussed.Conclusion
Although bivalirudin is not approved for cardiac surgery in the United States, it can be used in this setting in Canada as an anticoagulant in patients with heparin-induced thrombocytopenia provided the cardiac anesthesiologist is knowledgeable about potential complications from its use and knows how to manage or mitigate their incidence appropriately. During cardiopulmonary bypass, bivalirudin anticoagulation protocols must be thoroughly followed to attain optimal clinical outcomes. Additionally, further studies with bivalirudin are needed to determine the best monitoring modality and dosing regimen. 相似文献278.
Mayke BG Koek Erik Buskens Paul HA Steegmans Huib van Weelden Carla AFM Bruijnzeel-Koomen Vigfús Sigurdsson 《BMC medical research methodology》2006,6(1):39-11